secwatch.observer — SEC 8-K summary
======================================

Issuer:     Anika Therapeutics, Inc. (ANIK)
CIK:        0000898437
Form:       8-K
Filed at:   2026-02-26T23:59:59+00:00
Accession:  0001193125-26-073401
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Anika Q4 rev flat, FY rev -6%; guides 2026 rev $114-122.5M; GC Colleran to depart May 1
--------------------------------------------------------------------------------

- Q4 revenue $30.6M flat YoY; GAAP EPS $0.13, adjusted EPS $0.31; gross margin 63%.
- FY25 revenue $112.8M (-6%); GAAP loss ($0.70)/share; adjusted EPS $0.11; adjusted EBITDA $5.3M.
- Commercial Channel rev +22% Q4, +15% FY; OEM -12% Q4, -17% FY.
- FY26 guidance: rev $114-122.5M (1-9% growth); adj. EBITDA margin 5-10%; $15M buyback continuing.
- EVP, General Counsel David Colleran to depart May 1, 2026 under transition agreement.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/898437/000119312526073401/0001193125-26-073401-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/898437/000119312526073401/d106406d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-073401

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer